NASDAQ: FRMMForum Markets Inc Stock
$3.00-0.29 (-8.81%)
Updated Mar 5, 2026
FRMM Price
$3.00
Fair Value Price
N/A
Market Cap
$64.20M
52 Week Low
$2.91
52 Week High
$174.54
P/E
-0.02x
P/B
0.14x
P/S
72.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.11M
Earnings
-$225.11M
Gross Margin
100%
Operating Margin
-5,476%
Profit Margin
-5,671.9%
Debt to Equity
1.27
Operating Cash Flow
-$19M
Beta
1.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FRMM Overview
ETHZilla Corp. is a technology company in the decentralized finance (DeFi) industry, which intends to connect financial institutions, businesses, and organizations worldwide by enabling secure, accessible blockchain transactions through Ethereum Network protocol implementations. It continues to maintain the deployment and development of its biotech and gaming operations. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FRMM's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FRMM
Ranked#467 of 476
Ranked#467 of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $34.68 | A | |
| $15.83 | A | |
| $183.63 | A |
Be the first to know about important FRMM news, forecast changes, insider trades & much more!
FRMM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FRMM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FRMM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FRMM is good value based on its book value relative to its share price (0.14x), compared to the US Biotechnology industry average (4.81x)
P/B vs Industry Valuation
FRMM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FRMM due diligence checks available for Premium users.
Valuation
FRMM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
32.53x
Market
37.5x
FRMM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.14x
Industry
4.81x
FRMM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FRMM's financial health
Profit margin
Revenue
$4.1M
Net Income
-$216.7M
Profit Margin
-5,273.3%
FRMM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FRMM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.0B
Liabilities
$564.2M
Debt to equity
1.27
FRMM's short-term assets ($561.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FRMM's short-term assets ($561.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FRMM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FRMM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.4M
Investing
$0.0
Financing
$825.5M
FRMM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FRMM vs Biotech Stocks
Forum Markets Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.